Polypeptides

1. A polypeptide comprising an amino acid sequence which is an analogue of SEQ ID No: 2 wherein:

said analogue comprises a glutamic acid residue at position 14 and a proline residue at position 37 or said analogue comprises a glutamic acid residue at position 14 and an amino acid residue at position 35 which is selected from the group consisting of His, Arg, Lys, Asp, Glu and Gln;

wherein the amino acid sequence numbering of the analogue corresponds to the amino acid numbering sequence of SEQ ID No: 2; and

optionally the polypeptide has at least one substituent attached to at least one of its amino acid residues.

2. The polypeptide according to claim 1 wherein said analogue comprises a residue at position 17 selected from the group consisting of histidine, arginine, lysine and valine.

3. The polypeptide of claim 1 wherein said analogue comprises a residue at position 37 which is selected from the group consisting of proline and tyrosine.

4. The polypeptide of claim 1 wherein said analogue comprises a residue at position 35 selected from the group consisting of histidine, arginine, lysine, aspartic acid, glutamic acid, asparagine and glutamine.

5. The polypeptide of claim 1 wherein the analogue comprises an amino acid residue at position 14 which is glutamic acid, a residue at position 17 which is arginine and a residue at position 37 which is proline.

6. The polypeptide of claim 1 wherein the analogue of SEQ ID No: 2comprises:

(SEQ ID No: 3)

Xaa 1 -Cys-Xaa 3 -Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-

Xaa 17 -Xaa 18 -Ser-Ser-Xaa 21 -Xaa 22 -Phe-Gly-Pro-Xaa 26 -Leu-Pro-Pro-Thr-Xaa 31 -

Val-Gly-Ser-Xaa 35 -Thr-Xaa 37 ;

Formula (I)

wherein

Xaa 1 is deleted or independently selected from Ala, Cys, Glu, Gly, His, Arg, Ser and Lys;

Xaa 3 is independently selected from Gly, His, Arg, Ser and Asn;

Xaa 17 is independently selected from His, Arg, Lys and Val;

Xaa 18 is independently selected from Arg, Lys and His;

Xaa 21 is independently selected from Ala, Lys, Gln, Ser and Asn;

Xaa 22 is independently selected from Glu, Gln, Ser, Thr and Asn;

Xaa 26 is independently selected from Pro, Arg and Ile;

Xaa 31 is independently selected from Ser, Glu, Asp and Asn;

Xaa 35 is independently selected from His, Arg, Lys, Asp and Glu;

Xaa 37 is independently selected from Pro and Tyr;

and wherein the C-terminal may optionally be derivatized.

7. The polypeptide of claim 1 wherein at least one substituent is attached to at least one amino acid residue of said polypeptide.

8. The polypeptide of claim 1 wherein the substituent group is selected from the group consisting of C20diacid, C20diacid-γGlu, C20diacid-γGlu-γGlu, C20diacid-γGlu-γGlu- γGlu, C20diacid-OEG, C20diacid-γGlu-OEG, C20diacid-γGlu-OEG- OEG, C18diacid-γGlu, C16diacid-γGlu, and C14diacid-γGlu.

9. The polypeptide of claim 1 wherein a substituent is attached to the α-amino group of the N-terminal amino acid residue or to a Lys residue.

10. The polypeptide of claim 1 selected from the group consisting of any one of the polypeptides presented in Table 9, wherein the polypeptide is not N-alpha-[2-(2-{2- [2-(2- {2-[(S)-4-Carboxy-4-(19-carboxyheptadecanoylamino) butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}etoxy )acetyl]-D-Arg-D-Arg-[Glu14,His17,Arg18,Ala21,Ser35]-pramlintide.

11. A method for treating type 2diabetes or obesity, comprising administering the polypeptide of claim 1 .

12. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable excipient.

13. A process for preparing a pharmaceutical composition comprising mixing the polypeptide of claim 1 with at least one pharmaceutically acceptable excipient.

14. The polypeptide according to claim 1 wherein said analogue comprises a residue at position 17 selected from the group consisting of histidine and arginine.

15. The polypeptide according to claim 1 wherein said analogue comprises an arginine residue at position 17.

16. The polypeptide of claim 1 wherein said analogue comprises a proline residue at position 37.

17. The polypeptide of claim 1 wherein said analogue comprises a residue at position 35 selected from the group consisting of histidine, glutamic acid, and asparagine.

18. The polypeptide of claim 1 wherein said analogue comprises a residue at position 35 selected from the group consisting of histidine and asparagine.

19. The polypeptide of claim 1 wherein said analogue comprises an asparagine residue at position 35.